Results 11 to 20 of about 20,077 (158)

Pharmacokinetics of Aztreonam-Avibactam After Single- and Multiple-Dose Administration: A Phase 1, Open-Label Study in Healthy Chinese Participants and Ethnic Comparison with Non-Chinese Participants. [PDF]

Clin Pharmacol Drug Dev
ABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Wang J, He J, Wu J, Zhang J, Ma Y, Ren X, Wei H, Zhang C, Zhu H, Raber SR, Cong S.   +10 more
europepmc   +2 more sources

Aztreonam: clinical and pharmacological characteristics at the present stage [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections.
Popov D.A., Zubareva N.A., Parshakov A.A.   +2 more
doaj   +1 more source

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

Antibiotics, 2022
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati, Davide Fiore Bavaro, Lucia Diella, Nicolò De Gennaro, Francesco Di Gennaro, Annalisa Saracino   +5 more
doaj   +1 more source

Direct Detection of Extended Spectrum β-Lactamases from Positive Blood Cultures by using Aztreonam and Clavulanate [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Bacterial Sepsis by Multidrug Resistant Gram Negative Bacilli (MDRGNB) producing Extended Spectrum β-Lactamases (ESBL) is one of the major causes of mortality and morbidity in hospitals.
Renji Francis, Ambica Rangaiah, Kusuma Gowdra Rangappa, Shwetha Jinnahalli Venugopal   +3 more
doaj   +1 more source

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model

Antibiotics, 2021
Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options.
Mao Hagihara, Hideo Kato, Toshie Sugano, Hayato Okade, Nobuo Sato, Yuichi Shibata, Daisuke Sakanashi, Jun Hirai, Nobuhiro Asai, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo   +11 more
doaj   +1 more source

Antimicrobial therapy of sepsis caused by carbapenem-resistant Klebsiella pneumoniae in patients with hematological malignancies [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2022
Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae. Materials and Methods.
Barantsevich N.E., Barantsevich E.P.
doaj   +1 more source

Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring

Безопасность и риск фармакотерапии, 2022
Aztreonam is the only approved monocyclic β-lactam antibiotic for human use that is active against Gram-negative aerobes, primarily Pseudomonas аeruginosa. Aztreonam has been used for more than 35 years, and aztreonam lysine has been on the market for 15
E. A. Sokova, V. V. Arkhipov, A. S. Kazakov, B. K. Romanov, R. N. Alyautdin, M. V. Zhuravleva   +5 more
doaj   +1 more source

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates

Microbiology Spectrum, 2021
Ceftazidime-avibactam (CZA) has emerged as a promising solution to the lack of new antibiotics against Pseudomonas aeruginosa infections. Data from in vitro assays of CZA combinations, however, are scarce. The objective of our study was to perform a time-
María M. Montero, Sandra Domene Ochoa, Carla López-Causapé, Sonia Luque, Luisa Sorlí, Núria Campillo, Inmaculada López Montesinos, Eduardo Padilla, Núria Prim, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada   +12 more
doaj   +1 more source

Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa

mBio, 2017
While much attention has been focused on acquired antibiotic resistance genes, chromosomal mutations may be most important in chronic infections where isolated, persistently infecting lineages experience repeated antibiotic exposure.
Peter Jorth, Kathryn McLean, Anina Ratjen, Patrick R. Secor, Gilbert E. Bautista, Sumedha Ravishankar, Amir Rezayat, Jayanthi Garudathri, Joe J. Harrison, Rachel A. Harwood, Kelsi Penewit, Adam Waalkes, Pradeep K. Singh, Stephen J. Salipante   +13 more
doaj   +1 more source

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

Frontiers in Medicine, 2023
Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of ...
Yanis Merad, Anne Conrad, Anne Conrad, Anne Conrad, Anne Conrad, Sophie Brosset, Sophie Brosset, Axel Schmidt, Axel Schmidt, Camille Hanriat, Camille Hanriat, Sebastien Lustig, Sebastien Lustig, Sebastien Lustig, Frederic Laurent, Frederic Laurent, Frederic Laurent, Frederic Laurent, Camille Kolenda, Camille Kolenda, Camille Kolenda, Camille Kolenda, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Tiphaine Roussel-Gaillard, Cecile Batailler, Cecile Batailler, Cecile Batailler, Tristan Ferry, Tristan Ferry, Tristan Ferry, Tristan Ferry, Lyon BJI Study group   +32 more
doaj   +1 more source